Heron sells assets to CorMedix for $145M upfront; Faeth's stock tumbles

Plus, news about Immunovant, Abeona Therapeutics, Ellodi Pharmaceuticals, Spruce Biosciences, Adrenyx Biosciences, Edesa Biotech, Kyorin Pharmaceutical, Charles River Laboratories, Frontage, Compass Pathways, Johnson & Johnson, Veradermics and Valneva. CorMedix acquires Heron portfolio: CorMedix